Merck and Moderna said Wednesday that a personalized mRNA vaccine reduced the risk of melanoma recurrence in a large late-stage clinical trial.
This development marks a significant step toward personalized cancer treatment, potentially offering a new way to prevent the return of one of the most deadly forms of skin cancer in high-risk patients.
The trial enrolled more than 1,100 patients [1]. Participants were categorized as high-risk, meaning they had a higher probability of the cancer returning after initial treatment. The vaccine uses messenger RNA technology to trigger an immune response tailored to the specific mutations of an individual's tumor.
The companies said the vaccine cut the risk of melanoma recurrence [2]. The treatment was designed to work in tandem with existing therapies to identify and destroy remaining cancer cells that could lead to a relapse.
Market reactions to the clinical data were immediate. Moderna's stock more than doubled after the announcement [3]. Investors reacted to the potential for mRNA technology to expand beyond infectious diseases into oncology.
The results were released on Aug. 19, 2026 [4]. While the companies highlighted the promise of the results, the long-term efficacy of the vaccine will continue to be monitored as part of the trial's follow-up protocols.
“A personalized mRNA vaccine reduced the risk of melanoma recurrence in a large late-stage clinical trial.”
The success of this trial suggests that personalized medicine—where a drug is engineered for a specific patient's genetic profile—is moving from theoretical research into viable clinical application. By reducing recurrence rates in high-risk melanoma patients, this approach could establish a blueprint for treating other solid tumors using mRNA technology.
